NHS Logo
Image from Google Jackets

Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability:outcomes following a shortened 6-week protocol.

By: Contributor(s): Publication details: 2010ISSN:
  • 14644096
Uniform titles:
  • BJU international.
Online resources: Summary: <p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;"><strong>OBJECTIVE:</strong> To describe our initial outcome data&nbsp;<span class="highlight">following</span>&nbsp;a&nbsp;<span class="highlight">shortened</span>&nbsp;<span class="highlight">6-week</span>&nbsp;<span class="highlight">treatment</span>&nbsp;<span class="highlight">protocol</span>&nbsp;with&nbsp;<span class="highlight">percutaneous</span>&nbsp;<span class="highlight">tibial</span><span class="highlight">nerve</span>&nbsp;<span class="highlight">stimulation</span>&nbsp;(PTNS) in women with overactive bladder syndrome (OABS) unresponsive to bladder retraining and anticholinergic therapy.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">PATIENTS AND METHODS:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">This was a prospective observational study over a 6-month period. In all, 43 women with OABS refractory to medical therapy were treated with a&nbsp;<span class="highlight">shortened</span>&nbsp;PTNS&nbsp;<span class="highlight">protocol</span>&nbsp;that consisted of 6 weekly 30 min sessions. Bladder symptom diaries and health-related quality of life (HRQL) assessed using the short-form seven-item self-report. Incontinence Impact Questionnaire (IIQ-7) were completed before and after&nbsp;<span class="highlight">treatment</span>. A positive response was defined as: (i) OAB symptoms no longer being bothersome; (ii) reduction by half in frequency episodes and (iii) reduction by 25% in IIQ-7<span class="highlight">outcomes</span>.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">RESULTS:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">All 43 women (median age 55.3 years) completed six treatments with a positive response rate of 69.7%. In the positive responders, the median daytime and nocturnal frequency was reduced by half after 6 weeks of&nbsp;<span class="highlight">treatment</span>&nbsp;(11.8 vs 6.9 and 3.5 vs 1.8, respectively, P < 0.05) and the patients reported fewer urge leak episodes per 24 h (median 3.5 vs 2.4, P < 0.05). The median IIQ-7 scores improved by 25% (30.4 vs 24.3, P < 0.05) in responders, while the median number of pads changed in 24 h also decreased by 34% (3.8 vs 2.5, P < 0.05). The median acceptability of the technique when scored by Visual Analogue Score was 9.6/10 and no side-effects were reported.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">CONCLUSION:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">A&nbsp;<span class="highlight">shortened</span>&nbsp;<span class="highlight">6-week</span>&nbsp;<span class="highlight">treatment</span>&nbsp;with PTNS appears to be successful, with a significant reduction in symptoms and improvement in HRQL. This early data suggest that the duration of&nbsp;<span class="highlight">treatment</span>&nbsp;for peripheral neuromodulation can be halved compared with the conventional 12 weeks, which would make it more acceptable and cost effective for patients. A randomised controlled trial of 6 weeks vs 12 weeks of PTNS therapy would be useful in determining the optimal duration of&nbsp;<span class="highlight">treatment</span></span></p>
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Home library Collection Class number Status Date due Barcode
UNKNOWN Ferriman Information and Library Service (North Middlesex) Online Staff publications for NMDX Available

NMUH Staff Publications

Available in print at Ferriman Library

106

&lt;p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;strong&gt;OBJECTIVE:&lt;/strong&gt; To describe our initial outcome data&amp;nbsp;&lt;span class="highlight"&gt;following&lt;/span&gt;&amp;nbsp;a&amp;nbsp;&lt;span class="highlight"&gt;shortened&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;6-week&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;protocol&lt;/span&gt;&amp;nbsp;with&amp;nbsp;&lt;span class="highlight"&gt;percutaneous&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;tibial&lt;/span&gt;&lt;span class="highlight"&gt;nerve&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;stimulation&lt;/span&gt;&amp;nbsp;(PTNS) in women with overactive bladder syndrome (OABS) unresponsive to bladder retraining and anticholinergic therapy.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"&gt;&lt;span style="font-size: 8pt;"&gt;PATIENTS AND METHODS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"&gt;&lt;span style="font-size: 8pt;"&gt;This was a prospective observational study over a 6-month period. In all, 43 women with OABS refractory to medical therapy were treated with a&amp;nbsp;&lt;span class="highlight"&gt;shortened&lt;/span&gt;&amp;nbsp;PTNS&amp;nbsp;&lt;span class="highlight"&gt;protocol&lt;/span&gt;&amp;nbsp;that consisted of 6 weekly 30 min sessions. Bladder symptom diaries and health-related quality of life (HRQL) assessed using the short-form seven-item self-report. Incontinence Impact Questionnaire (IIQ-7) were completed before and after&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;. A positive response was defined as: (i) OAB symptoms no longer being bothersome; (ii) reduction by half in frequency episodes and (iii) reduction by 25% in IIQ-7&lt;span class="highlight"&gt;outcomes&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"&gt;&lt;span style="font-size: 8pt;"&gt;RESULTS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"&gt;&lt;span style="font-size: 8pt;"&gt;All 43 women (median age 55.3 years) completed six treatments with a positive response rate of 69.7%. In the positive responders, the median daytime and nocturnal frequency was reduced by half after 6 weeks of&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;(11.8 vs 6.9 and 3.5 vs 1.8, respectively, P &amp;lt; 0.05) and the patients reported fewer urge leak episodes per 24 h (median 3.5 vs 2.4, P &amp;lt; 0.05). The median IIQ-7 scores improved by 25% (30.4 vs 24.3, P &amp;lt; 0.05) in responders, while the median number of pads changed in 24 h also decreased by 34% (3.8 vs 2.5, P &amp;lt; 0.05). The median acceptability of the technique when scored by Visual Analogue Score was 9.6/10 and no side-effects were reported.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"&gt;&lt;span style="font-size: 8pt;"&gt;CONCLUSION:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"&gt;&lt;span style="font-size: 8pt;"&gt;A&amp;nbsp;&lt;span class="highlight"&gt;shortened&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;6-week&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;with PTNS appears to be successful, with a significant reduction in symptoms and improvement in HRQL. This early data suggest that the duration of&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;for peripheral neuromodulation can be halved compared with the conventional 12 weeks, which would make it more acceptable and cost effective for patients. A randomised controlled trial of 6 weeks vs 12 weeks of PTNS therapy would be useful in determining the optimal duration of&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

There are no comments on this title.

to post a comment.